<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04553926</url>
  </required_header>
  <id_info>
    <org_study_id>D0817R00010</org_study_id>
    <nct_id>NCT04553926</nct_id>
  </id_info>
  <brief_title>'OLAP' (OLAparib Regulatory Post-marketing Surveillance)</brief_title>
  <acronym>OLAP</acronym>
  <official_title>Lynparza Tablet (Olaparib) Regulatory Post-Marketing Surveillance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The objectives of this study are to assess safety and effectiveness of Lynparza tablet&#xD;
      (olaparib, hereinafter &quot;the study drug&quot;) in a real world setting in patients who are&#xD;
      prescribed with the study drug according to the approved indications in South Korea&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: To assess the safety of the study drug for patients prescribed with the&#xD;
      study drug under the approved indications in South Korea Secondary Objective: To assess&#xD;
      effectiveness of the study drug for patients prescribed with the study drug under the&#xD;
      approved indication in South Korea Exploratory Objective: To assess effectiveness of the&#xD;
      study drug for ovarian cancer patients diagnosed as Homologous Recombination Deficiency (HRD)&#xD;
      positive via locally available validated HRD test and prescribed with the study drug under&#xD;
      the approved indication in South Korea&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (adverse events (AEs), serious AEs (SAEs), adverse drug reactions(ADRs), serious ADRs (SADRs), unexpected AEs/ADRs)</measure>
    <time_frame>For about 1 year since the first dose of the study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>6-month real-world Progression free survival (rwPFS)</measure>
    <time_frame>For about 1 year since the first dose of the study drug</time_frame>
    <description>In this PMS, the secondary/pre-specified endpoint is not just PFS, but real-world PFS (rwPFS). That means the sponsor cannot claim investigator/patients to visit hospital for study assessment purposes.&#xD;
We, study sponsor, can only assess and record patient's disease progression status when patients visit hospital for their original follow-up. That's why we need further +50% duration for assessing rwPFS.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>1-year real-world Progression free survival (rwPFS)</measure>
    <time_frame>For about 18 months since the first dose of the study drug</time_frame>
    <description>for the exploratory objective, &quot;In this PMS, the secondary/pre-specified endpoint is not just PFS, but real-world PFS (rwPFS). That means the sponsor cannot claim investigator/patients to visit hospital for study assessment purposes.&#xD;
We, study sponsor, can only assess and record patient's disease progression status when patients visit hospital for their original follow-up. That's why we need further +50% duration for assessing rwPFS.</description>
  </other_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        On active study drug treatment according to the approved local label.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Eligible for the study drug treatment according to the approved label in South Korea&#xD;
&#xD;
          2. Provision of signed and dated written informed consent by the patient or legally&#xD;
             acceptable representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of hypersensitivity to excipients of the study drug or to drugs with a similar&#xD;
             chemical structure or class to the study drug&#xD;
&#xD;
          2. Prior exposure to any Polyadenosine 5'diphosphoribose polymerase (PARP) inhibitors,&#xD;
             including the study drug&#xD;
&#xD;
          3. Pregnant and/or breast feeding&#xD;
&#xD;
          4. Current participation in any interventional trial&#xD;
&#xD;
          5. Other off-label indications according to the approved label&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chungcheongnam-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2020</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

